Orna Therapeutics Advances CAR Therapies: Potential Breakthroughs in Autoimmune Disease Treatment

### Orna Therapeutics Develops Innovative CAR Therapies to Combat Autoimmune Diseases

Orna Therapeutics, a biotechnology firm dedicated to engineering immune cells for treating autoimmune and oncology diseases, presents promising preclinical data for its anti-CD19 panCAR program (ORN-252) and anti-BCMA panCAR program. At the 67th American Society of Hematology Annual Meeting, the company reveals that ORN-252 demonstrates significant B cell depletion and reduced anti-dsDNA titers in humanized lupus models. Notably, the therapy achieves these results even at low doses, achieving complete peripheral and splenic B cell depletion in non-human primate studies with doses as minimal as 0.1 mg/kg. This effectiveness positions ORN-252 as a pioneering approach in the treatment of B cell-related autoimmune conditions, offering hope for patients who currently face limited options.

The anti-BCMA panCAR program also shows remarkable potential, exhibiting durable plasma cell depletion in preclinical models. This reinforces Orna's strategy of developing in vivo CAR therapies that do not require lymphodepletion preconditioning, a typical hurdle in traditional CAR T-cell therapies. Joseph Bolen, Ph.D., CEO of Orna, underscores the innovative nature of the company's non-viral, scalable platform that utilizes proprietary circular RNA technology alongside a lipid nanoparticle delivery system. This advanced delivery mechanism is designed to enhance the therapeutic potential of their CAR programs, making them more accessible and efficient for clinical application.

Looking ahead, Orna Therapeutics sets ambitious goals with plans to submit its first Clinical Trial Application for ORN-252 by the end of 2025, followed by the initiation of its first human study in early 2026. This timeline marks a significant milestone for the company, as it transitions from promising preclinical findings to real-world applications. The encouraging results shared at the conference highlight Orna's commitment to advancing therapies aimed at B cell-related autoimmune diseases and oncology, potentially reshaping treatment paradigms and offering new hope to patients.

In addition to its impressive preclinical advancements, Orna Therapeutics' focus on non-viral delivery methods reflects a growing trend in biotechnology towards simplifying and enhancing therapeutic processes. This evolution aims not only to improve the efficacy of treatments but also to streamline production and reduce costs, making advanced therapies more accessible to diverse patient populations.

As the landscape of immunotherapy continues to evolve, companies like Orna Therapeutics are at the forefront, pushing the boundaries of what's possible in autoimmune and oncology treatment. Their innovative approaches could pave the way for breakthroughs that transform patient care and expand therapeutic options for complex diseases.